N. Yu. Nikishina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
N. Yu. Nikishina has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
18 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
14 shared publications - Sergey Soloviev
V.A. Nasonova Research Institute of Rheumatology
13 shared publications - A. A. Mesnyankina
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - Tatiana M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
4 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
3 shared publications
Latest Publications
- Open Access
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 98-105
Selective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 98-105
Open AccessSelective plasmosorption of extracellular DNA and NETs in patients with difficult-to-treat rheumatoid arthritis (first clinical experience)
Rheumatoid arthritis (RA) associated with interstitial lung disease (RA-ILD) represents a distinct clinical and pathogenetic phenotype characterized by high inflammatory activity, seropositivity, and systemic manifestations. In recent years, increasing attention has been directed to the role of extracellular DNA and neutrophil extracellular traps (NETs) in RA pathogenesis. This report presents the first case of selective plasmosorption of extracellular DNA and NETs in a patient with RA-ILD. The therapy was associated with a decrease in joint pain and stiffness and improvement of general condition. Laboratory parameters were also monitored dynamically. This clinical case demonstrates the potential of DNA-containing structure plasmosorption as an adjunctive method to enhance the effect of therapy with biological disease modifying antirheumatic drugs in refractory RA.
- Open Access
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 26-33
Clinical significance of urinary soluble CD11b and CD163 receptor levels in ANCA-associated vasculitides
Objective. To assess the diagnostic value of urinary soluble CD11b and CD163 receptor levels (U-CD11b and U-CD163) in patients with antineutrophil cytoplasmic antibody-associated systemic vasculitides (AAV).Material and methods. This cross-sectional study included 48 patients (21 men, 27 women; median age 52 [31; 67] years) with a confirmed diagnosis of AAV: granulomatosis with polyangiitis (GPA) in 38, microscopic polyangiitis (MPA) in 8, and eosinophilic granulomatosis with polyangiitis in 2. Patients were stratified into two groups: Group 1, AAV without kidney involvement (n=25); Group 2, AAV with kidney involvement (n=23). A comparison Group 3 comprised 13 patients with systemic lupus erythematosus (SLE) and biopsy-proven kidney involvement (4 men, 9 women; median age 34 [29.0; 43.4] years). All patients underwent standard clinical, laboratory, and instrumental evaluations. U-CD11b and U-CD163 were measured by ELISA using kits ELH-ITGAM-1 (human CD11b) and DC1630 (human CD163) (China). Reference values for U-CD11b and U-CD163, established as the 95th percentile in volunteers without autoimmune disease, were 5.7 and 41.4 ng/mL, respectively. In 10 patients (2 with GPA, 1 with MPA, and 7 with SLE) glomerulonephritis (GN) was verified by vital renal biopsy.Results and discussion. GN was identified in 36 patients (23 with AAV, 13 with SLE). U-CD11b level was significantly higher in 8 (61.5%) SLE patients than in 22 (46%) AAV patients (median 8.2 [4.5; 11.1] and 5.1 [2.7; 8.1] ng/mol, respectively; p=0.02). Conversely, U-CD163 level was higher in 13 (48%) AAV patients (median 29.8 [3.5; 159.1] ng/mmol) than in 6 (46.1%) SLE patients (22.6 [12.7; 148.5] ng/mol), p=0.04. Elevated U-CD11b was detected more frequently in SLE and in AAV with kidney involvement than in AAV without kidney involvement (61.5%, 56.5%, and 36%, respectively; p=0.001), with the highest median in Group 3 (median 8.2 [4.5; 11.1] ng/mmol). Elevated U-CD163 was more frequent in Groups 3 and 2 than in Group 1 (46.1%, p=0.009; 43.4%, p=0.025; and 12%, respectively), with the highest median in Group 2 (34.9 [9.3; 159.1] ng/mmol). However, between-group differences in the frequencies of elevated U-CD11b and U-CD163 were not statistically significant. In Group 1, increases in U-CD11b (36% of cases) and U-CD163 (12%) levels were also observed. Elevated biomarker levels were associated with higher disease activity but not with GN morphological classes in AAV or SLE.Conclusion. U-CD11b and U-CD163 levels may reflect the severity of renal inflammatory involvement in patients with AAV and SLE. Further studies are needed to determine the diagnostic utility of these biomarkers.
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 26-33
Open AccessClinical significance of urinary soluble CD11b and CD163 receptor levels in ANCA-associated vasculitides
Objective. To assess the diagnostic value of urinary soluble CD11b and CD163 receptor levels (U-CD11b and U-CD163) in patients with antineutrophil cytoplasmic antibody-associated systemic vasculitides (AAV).Material and methods. This cross-sectional study included 48 patients (21 men, 27 women; median age 52 [31; 67] years) with a confirmed diagnosis of AAV: granulomatosis with polyangiitis (GPA) in 38, microscopic polyangiitis (MPA) in 8, and eosinophilic granulomatosis with polyangiitis in 2. Patients were stratified into two groups: Group 1, AAV without kidney involvement (n=25); Group 2, AAV with kidney involvement (n=23). A comparison Group 3 comprised 13 patients with systemic lupus erythematosus (SLE) and biopsy-proven kidney involvement (4 men, 9 women; median age 34 [29.0; 43.4] years). All patients underwent standard clinical, laboratory, and instrumental evaluations. U-CD11b and U-CD163 were measured by ELISA using kits ELH-ITGAM-1 (human CD11b) and DC1630 (human CD163) (China). Reference values for U-CD11b and U-CD163, established as the 95th percentile in volunteers without autoimmune disease, were 5.7 and 41.4 ng/mL, respectively. In 10 patients (2 with GPA, 1 with MPA, and 7 with SLE) glomerulonephritis (GN) was verified by vital renal biopsy.Results and discussion. GN was identified in 36 patients (23 with AAV, 13 with SLE). U-CD11b level was significantly higher in 8 (61.5%) SLE patients than in 22 (46%) AAV patients (median 8.2 [4.5; 11.1] and 5.1 [2.7; 8.1] ng/mol, respectively; p=0.02). Conversely, U-CD163 level was higher in 13 (48%) AAV patients (median 29.8 [3.5; 159.1] ng/mmol) than in 6 (46.1%) SLE patients (22.6 [12.7; 148.5] ng/mol), p=0.04. Elevated U-CD11b was detected more frequently in SLE and in AAV with kidney involvement than in AAV without kidney involvement (61.5%, 56.5%, and 36%, respectively; p=0.001), with the highest median in Group 3 (median 8.2 [4.5; 11.1] ng/mmol). Elevated U-CD163 was more frequent in Groups 3 and 2 than in Group 1 (46.1%, p=0.009; 43.4%, p=0.025; and 12%, respectively), with the highest median in Group 2 (34.9 [9.3; 159.1] ng/mmol). However, between-group differences in the frequencies of elevated U-CD11b and U-CD163 were not statistically significant. In Group 1, increases in U-CD11b (36% of cases) and U-CD163 (12%) levels were also observed. Elevated biomarker levels were associated with higher disease activity but not with GN morphological classes in AAV or SLE.Conclusion. U-CD11b and U-CD163 levels may reflect the severity of renal inflammatory involvement in patients with AAV and SLE. Further studies are needed to determine the diagnostic utility of these biomarkers.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 115-120
Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
Systemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has been increasingly used in recent years for the treatment of LN.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 115-120
Open AccessEfficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
Systemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has been increasingly used in recent years for the treatment of LN.
- Open Access
- 21 August 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 93-98
Long-term belimumab therapy in patients with systemic lupus erythematosus
Therapy of systemic lupus erythematosus (SLE) remains a difficult task. Long-term use of glucocorticoids (GC) and cytostatic drugs significantly improves the prognosis of life, but at the same time contributes to the accumulation of irreversible damage to the internal organs and, as a result, to the deterioration of the quality of life, disability, social disadaptation and premature mortality. Preventing such consequences, achieving and maintaining long-term remission and reducing the need in high and medium doses of GC remain important tasks in SLE therapy, which has been facilitated by introduction of biologic disease-modifying antirheumatic drugs (bDMARDs) into clinical practice. Belimumab is the first bDMARD to be approved for the treatment of SLE. The accumulated experience allows conclusions to be drawn about its therapeutic properties and efficacy in a specific subtype of the disease, but feasibility and safety of long-term use of bDMARDs have not been sufficiently investigated. In this article, three clinical cases are presented in which belimumab was successfully used over a period of 9–10 years.
- 21 August 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (4) , 93-98
Open AccessLong-term belimumab therapy in patients with systemic lupus erythematosus
Therapy of systemic lupus erythematosus (SLE) remains a difficult task. Long-term use of glucocorticoids (GC) and cytostatic drugs significantly improves the prognosis of life, but at the same time contributes to the accumulation of irreversible damage to the internal organs and, as a result, to the deterioration of the quality of life, disability, social disadaptation and premature mortality. Preventing such consequences, achieving and maintaining long-term remission and reducing the need in high and medium doses of GC remain important tasks in SLE therapy, which has been facilitated by introduction of biologic disease-modifying antirheumatic drugs (bDMARDs) into clinical practice. Belimumab is the first bDMARD to be approved for the treatment of SLE. The accumulated experience allows conclusions to be drawn about its therapeutic properties and efficacy in a specific subtype of the disease, but feasibility and safety of long-term use of bDMARDs have not been sufficiently investigated. In this article, three clinical cases are presented in which belimumab was successfully used over a period of 9–10 years.
- Open Access
- 15 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 71-77
Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
This article describes the experience of using the type I interferon inhibitor anifrolumab (AFM) in a patient with a torpid course of systemic lupus erythematosus. The reason for prescribing AFM was the need for a quick achievement of low disease activity due to a planned hip replacement. Dynamic observational data over a six-month period confirmed that AFM enables a rapid achievement of low disease activity without increasing the dose of glucocorticoids, significantly improve the patient's quality of life and even prepare them for major surgery without exacerbating the underlying process.
- 15 June 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (3) , 71-77
Open AccessRapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
This article describes the experience of using the type I interferon inhibitor anifrolumab (AFM) in a patient with a torpid course of systemic lupus erythematosus. The reason for prescribing AFM was the need for a quick achievement of low disease activity due to a planned hip replacement. Dynamic observational data over a six-month period confirmed that AFM enables a rapid achievement of low disease activity without increasing the dose of glucocorticoids, significantly improve the patient's quality of life and even prepare them for major surgery without exacerbating the underlying process.
- Open Access
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 75-80
The first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 75-80
Open AccessThe first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown etiology characterized by the overproduction of autoantibodies against various components of the nucleus of the patient's own cells with the development of immunoinflammatory tissue damage. In recent years, more and more data have accumulated on the involvement of neutrophils in the development of the clinical symptoms of SLE, and DNA-containing structures and neutrophil extracellular traps (NETs) playing an important role in this process. Effective neutralization of NETs in SLE can be achieved by removing circulating proteins and molecules associated with NETs from the bloodstream by selective plasma sorption of DNA using the NucleoCapture Device.This article describes the case of a patient who underwent three plasma sorption sessions aiming to suppress the activity of SLE. During the therapy, significant positive dynamics were achieved: the SLEDAI-2K index decreased from 32 to 12 points, the number of leukocytes in the blood normalized, renal function improved, and the immunological activity of the disease decreased.
- Open Access
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 88-94
The role of repeat kidney biopsy in patients with lupus nephritis (case report)
Lupus nephritis (LN) occurs in 35–60% of patients with systemic lupus erythematosus (SLE), often in the early stages of the disease. LN is one of the most severe manifestations of SLE and, if not treated promptly and effectively, can lead to rapid and severe loss of kidney function. Despite modern pharmacotherapy, 5–20% of patients develop end-stage renal failure within 10 years of diagnosis of LN. The main principle of LN therapy is to prevent deterioration of renal function, but a consensus on outcome assessment criteria and clinically relevant short- and long-term goals for LN therapy has not yet been reached. There is increasing evidence of the importance of repeat kidney biopsies to assess the outcomes of the initial phase of therapy and to determine the long-term prognosis of renal failure. It is believed that the information obtained from repeat biopsies can help to make optimal treatment decisions and thus increase the likelihood of achieving a complete renal response in the short term and a more favorable renal prognosis in the long term.We describe a clinical case of a young patient with highly active SLE and morphologically confirmed class IV-S LN. Repeat biopsy and clinical and laboratory examination, had confirmed a clinical and laboratory remission of the disease on the background of the therapy. This made it possible to reduce the dose of methylpednisolone and cytostatic drugs (mycophenolate mofetil) and to discontinue therapy with biologic diseasemodifying antirheumatic drug (rituximab).
- 22 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 88-94
Open AccessThe role of repeat kidney biopsy in patients with lupus nephritis (case report)
Lupus nephritis (LN) occurs in 35–60% of patients with systemic lupus erythematosus (SLE), often in the early stages of the disease. LN is one of the most severe manifestations of SLE and, if not treated promptly and effectively, can lead to rapid and severe loss of kidney function. Despite modern pharmacotherapy, 5–20% of patients develop end-stage renal failure within 10 years of diagnosis of LN. The main principle of LN therapy is to prevent deterioration of renal function, but a consensus on outcome assessment criteria and clinically relevant short- and long-term goals for LN therapy has not yet been reached. There is increasing evidence of the importance of repeat kidney biopsies to assess the outcomes of the initial phase of therapy and to determine the long-term prognosis of renal failure. It is believed that the information obtained from repeat biopsies can help to make optimal treatment decisions and thus increase the likelihood of achieving a complete renal response in the short term and a more favorable renal prognosis in the long term.We describe a clinical case of a young patient with highly active SLE and morphologically confirmed class IV-S LN. Repeat biopsy and clinical and laboratory examination, had confirmed a clinical and laboratory remission of the disease on the background of the therapy. This made it possible to reduce the dose of methylpednisolone and cytostatic drugs (mycophenolate mofetil) and to discontinue therapy with biologic diseasemodifying antirheumatic drug (rituximab).
- Open Access
- 19 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 16–24
Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
Objective: to evaluate the efficacy and safety of the type I interferon (IFN) receptor inhibitor anifrolumab (AFM, Safnelo®) in patients with systemic lupus erythematosus (SLE) in real-life clinical practice over an observation period of 6 months.Material and methods. The prospective 6-month study included 21 patients with SLE fulfilling the 2012 SLICC criteria, predominantly women (n=17,81%), median age – 31 [27; 46] years, disease duration – 9 [6.0; 11.0] years. Standard laboratory values and immunological markers of SLE were examined in all patients. The SLEDAI-2K index was used to determine the activity of SLE, and the severity of the mucocutaneous syndrome was assessed using the Cutaneous Lupus Disease Area and Severity Index (CLASI) index. Organ damage was assessed using the SLICC/ACR Damage Index (DI). After 6 months, the achievement of low activity was assessed according to the Lupus Low Disease Activity State (LLDAS) indexResults and discussion. At the time of inclusion in the study, the mean SLEDAI-2K activity index for the group was 8 [6.0; 10.0] points, the median CLASI index – 8.6±8.2 points, 81% of patients had skin and mucosal lesions, 66% had non-erosive polyarthritis, and high immunological activity was observed in all cases. Various irreversible organ damage was observed in 86 of patients. The average DI was 2.2±1.5 points. At the start of AFM therapy, all patients received glucocorticoids (GCs) at a mean dose of 10.7±5.6 mg/day, 52% of patients received a dose above 10 mg/day, 76% of patients continued to take hydroxychloroquine, and 33% of patients took immunosuppressants. Significant positive dynamics were observed with AFM therapy. The average CLASI index for the group after 3 months of treatment was 1.2±4.1 points, after 6 months – 0.3±1.2 points (pConclusion. At a dose of 300 mg intravenously monthly AFM is a highly effective drug with a relatively good safety profile in patients with active SLE in whom autoantibodies are present and who do not respond adequately to standard therapy.
- 19 April 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 16–24
Open AccessEfficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
Objective: to evaluate the efficacy and safety of the type I interferon (IFN) receptor inhibitor anifrolumab (AFM, Safnelo®) in patients with systemic lupus erythematosus (SLE) in real-life clinical practice over an observation period of 6 months.Material and methods. The prospective 6-month study included 21 patients with SLE fulfilling the 2012 SLICC criteria, predominantly women (n=17,81%), median age – 31 [27; 46] years, disease duration – 9 [6.0; 11.0] years. Standard laboratory values and immunological markers of SLE were examined in all patients. The SLEDAI-2K index was used to determine the activity of SLE, and the severity of the mucocutaneous syndrome was assessed using the Cutaneous Lupus Disease Area and Severity Index (CLASI) index. Organ damage was assessed using the SLICC/ACR Damage Index (DI). After 6 months, the achievement of low activity was assessed according to the Lupus Low Disease Activity State (LLDAS) indexResults and discussion. At the time of inclusion in the study, the mean SLEDAI-2K activity index for the group was 8 [6.0; 10.0] points, the median CLASI index – 8.6±8.2 points, 81% of patients had skin and mucosal lesions, 66% had non-erosive polyarthritis, and high immunological activity was observed in all cases. Various irreversible organ damage was observed in 86 of patients. The average DI was 2.2±1.5 points. At the start of AFM therapy, all patients received glucocorticoids (GCs) at a mean dose of 10.7±5.6 mg/day, 52% of patients received a dose above 10 mg/day, 76% of patients continued to take hydroxychloroquine, and 33% of patients took immunosuppressants. Significant positive dynamics were observed with AFM therapy. The average CLASI index for the group after 3 months of treatment was 1.2±4.1 points, after 6 months – 0.3±1.2 points (pConclusion. At a dose of 300 mg intravenously monthly AFM is a highly effective drug with a relatively good safety profile in patients with active SLE in whom autoantibodies are present and who do not respond adequately to standard therapy.
- Open Access
- 29 February 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (1) , 55-64
Lupus nephritis – modern aspects of diagnosis and therapy. Part I
Lupus nephritis (LN) is considered to be one of the most frequent severe manifestations of systemic lupus erythematosus (SLE), its various colonic manifestations occur in at least 50% of SLE patients, both at the onset and at various stages of the disease, and develop LN is considered one of the most important predictors of mortality in SLE. The structure of nephritis is dominated by diffuse proliferative LN with clinical and morphological signs of progression and the rapid development of terminal renal failure. SLE is diagnosed based on the 2019 EULAR/ACR (European Alliance of Associations for Rheumatology/American College of Rheumatology) diagnostic classification criteria. To confirm the diagnosis, evaluate the prognosis, and choose the tactics of treating the dis-ease, all patients in the absence of contraindications require a kidney biopsy. In addition to LN, the spectrum of SLE-associated renal lesions includes vascular pathology represented by thrombotic microangiopathy, lupus vasculopathy or vasculitis, tubulointerstitial injury, and lupus podocytopathy.
- 29 February 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (1) , 55-64
Open AccessLupus nephritis – modern aspects of diagnosis and therapy. Part I
Lupus nephritis (LN) is considered to be one of the most frequent severe manifestations of systemic lupus erythematosus (SLE), its various colonic manifestations occur in at least 50% of SLE patients, both at the onset and at various stages of the disease, and develop LN is considered one of the most important predictors of mortality in SLE. The structure of nephritis is dominated by diffuse proliferative LN with clinical and morphological signs of progression and the rapid development of terminal renal failure. SLE is diagnosed based on the 2019 EULAR/ACR (European Alliance of Associations for Rheumatology/American College of Rheumatology) diagnostic classification criteria. To confirm the diagnosis, evaluate the prognosis, and choose the tactics of treating the dis-ease, all patients in the absence of contraindications require a kidney biopsy. In addition to LN, the spectrum of SLE-associated renal lesions includes vascular pathology represented by thrombotic microangiopathy, lupus vasculopathy or vasculitis, tubulointerstitial injury, and lupus podocytopathy.
- Open Access
- 17 February 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (1) , 28-34
Glucocorticoid toxicity index in patients with systemic lupus erythematosus (preliminary data)
Objective: to investigate the contribution of glucocorticoids (GC) to the development of irreversible organ damage in patients with systemic lupus erythematosus (SLE) using the GC toxicity index (GTI).Material and methods. The study included 65 patients with SLE who met the 2012 SLICC classification criteria. GTI, disease activity according to the SLEDAI-2K index and the SLICC damage index (DI) were determined in all patients, and standard laboratory and immunological tests were performed.Results and discussion. Patients were predominantly female (n=56, 86%), median disease duration was 76 [2; 288] months, SLEDAI-2K – 8.8 [0; 26], DI SLICC – 1.0 [0; 5], DI SLICC >0 was found in 28 (43%) patients. The median duration of GC therapy during the disease period was 66.0 [0; 288] months, maximum dose of GC – 32.7 [0; 80] mg, median of total GC dose during intravenous administration was 2942 [0; 17 812.5] mg, GTI at the time of enrolment in the study – 19 [0; 37] points. GTI >0 was present in 47 (72%) of 65 patients. GTI correlated with disease duration (r=0.33; p˂0.008); maximum dose of oral GCs (r=0.31; p˂0.012); duration of GC use (r=0.35; p˂0.005); DI SLICC (r=-0.43; p˂0.0001). In patients with an average disease duration of more than 3 years, GTI was significantly higher than in patients with a disease duration of 1–3 years (p=0.023).Conclusion. An GTI>0 was found in 72% of SLE patients, which increased significantly with disease duration. The GTI value was influenced by the duration of SLE, the duration of GC treatment and the maximum GC dose during the disease period. A statistically significant correlation was found between the GTI and the SLICC DI, allowing the GTI value to be used as an additional component in the assessment of the contribution of GCs to the development of irreversible organ damage in patients with SLE. It is recommended that GTI is assessed in all patients with SLE receiving long-term GC treatment for the purpose of dose adjustment.
- 17 February 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (1) , 28-34
Open AccessGlucocorticoid toxicity index in patients with systemic lupus erythematosus (preliminary data)
Objective: to investigate the contribution of glucocorticoids (GC) to the development of irreversible organ damage in patients with systemic lupus erythematosus (SLE) using the GC toxicity index (GTI).Material and methods. The study included 65 patients with SLE who met the 2012 SLICC classification criteria. GTI, disease activity according to the SLEDAI-2K index and the SLICC damage index (DI) were determined in all patients, and standard laboratory and immunological tests were performed.Results and discussion. Patients were predominantly female (n=56, 86%), median disease duration was 76 [2; 288] months, SLEDAI-2K – 8.8 [0; 26], DI SLICC – 1.0 [0; 5], DI SLICC >0 was found in 28 (43%) patients. The median duration of GC therapy during the disease period was 66.0 [0; 288] months, maximum dose of GC – 32.7 [0; 80] mg, median of total GC dose during intravenous administration was 2942 [0; 17 812.5] mg, GTI at the time of enrolment in the study – 19 [0; 37] points. GTI >0 was present in 47 (72%) of 65 patients. GTI correlated with disease duration (r=0.33; p˂0.008); maximum dose of oral GCs (r=0.31; p˂0.012); duration of GC use (r=0.35; p˂0.005); DI SLICC (r=-0.43; p˂0.0001). In patients with an average disease duration of more than 3 years, GTI was significantly higher than in patients with a disease duration of 1–3 years (p=0.023).Conclusion. An GTI>0 was found in 72% of SLE patients, which increased significantly with disease duration. The GTI value was influenced by the duration of SLE, the duration of GC treatment and the maximum GC dose during the disease period. A statistically significant correlation was found between the GTI and the SLICC DI, allowing the GTI value to be used as an additional component in the assessment of the contribution of GCs to the development of irreversible organ damage in patients with SLE. It is recommended that GTI is assessed in all patients with SLE receiving long-term GC treatment for the purpose of dose adjustment.